DNMT1 and acute myeloid leukemia: Another DNMT inhibitor (decitabine, clinically approved for myelodysplastic syndromes and AML) was also reported to achieve a higher rate of complete remission (79% in drug combination versus 32% for camrelizumab alone) and produce a long-term survival benefit (median PFS: 35 months in drug combination vs. 15.5 months with camrelizumab alone) when used in combination with camrelizumab (anti-PD-1 mAb) in relapsed Hodgkin lymphoma [128].